AAAAAA

   
Results: 1-14 |
Results: 14
Therapeutic choices for patients with hemophilia and high-titer inhibitors
Authors: Kulkarni, R Aledort, LM Berntorp, E Brackman, HH Brown, D Cohen, AR Ewing, NP Gringeri, A Gruppo, R Hoots, K Leissenger, C Peerlinck, K Poon, MC Wong, WY
Citation: R. Kulkarni et al., Therapeutic choices for patients with hemophilia and high-titer inhibitors, AM J HEMAT, 67(4), 2001, pp. 240-246
Drugs affecting blood coagulation, fibrinolysis, and hemostasis
Authors: Peerlinck, K Vermylen, J
Citation: K. Peerlinck et J. Vermylen, Drugs affecting blood coagulation, fibrinolysis, and hemostasis, SIDE EFFECT, 23, 2000, pp. 377-379
A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIIIC1 domain reduce factor VIII binding to von Willebrand factor
Authors: Jacquemin, M Lavend'homme, R Benhida, A Vanzieleghem, B d'Oiron, R Lavergne, JM Brackmann, HH Schwaab, R VandenDriessche, T Chuah, MKL Hoylaerts, M Gilles, JGG Peerlinck, K Vermylen, J Saint-Remy, JMR
Citation: M. Jacquemin et al., A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIIIC1 domain reduce factor VIII binding to von Willebrand factor, BLOOD, 96(3), 2000, pp. 958-965
Mutations in the fibrinogen A alpha gene account for the majority of casesof congenital afibrinogenemia
Authors: Neerman-Arbez, M de Moerloose, P Bridel, C Honsberger, A Schonborner, A Rossier, C Peerlinck, K Claeyssens, S Di Michele, D d'Oiron, R Dreyfus, M Laubriat-Bianchin, M Dieval, J Antonarakis, SE Morris, MA
Citation: M. Neerman-arbez et al., Mutations in the fibrinogen A alpha gene account for the majority of casesof congenital afibrinogenemia, BLOOD, 96(1), 2000, pp. 149-152
A human antibody directed to the factor VIIIC1 domain inhibits factor VIIIcofactor activity and binding to von Willebrand factor
Authors: Jacquemin, M Benhida, A Peerlinck, K Desqueper, B Elst, LV Lavend'homme, R d'Oiron, R Schwaab, R Bakkus, M Thielemans, K Gilles, JG Vermylen, J Saint-Remy, JM
Citation: M. Jacquemin et al., A human antibody directed to the factor VIIIC1 domain inhibits factor VIIIcofactor activity and binding to von Willebrand factor, BLOOD, 95(1), 2000, pp. 156-163
Acute myocardial infarction following administration of recombinant activated factor VII (Novo seven) in a patient with haemophilia A and inhibitor
Authors: Peerlinck, K Vermylen, J
Citation: K. Peerlinck et J. Vermylen, Acute myocardial infarction following administration of recombinant activated factor VII (Novo seven) in a patient with haemophilia A and inhibitor, THROMB HAEM, 82(6), 1999, pp. 1775-1776
Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes
Authors: Gilles, JGG Lavend'homme, R Peerlinck, K Jacquemin, MG Hoylaerts, M Jorieux, S Mazurier, C Vermylen, J Saint-Remy, JMR
Citation: Jgg. Gilles et al., Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes, THROMB HAEM, 82(1), 1999, pp. 40-45
Transfusion medicine
Authors: Vandenberghe, P Peerlinck, K
Citation: P. Vandenberghe et K. Peerlinck, Transfusion medicine, N ENG J MED, 341(2), 1999, pp. 125-125
Arterial occlusion and thrombus aspiration after total knee arthroplasty
Authors: Bellemans, J Stockx, L Peerlinck, K Vermylen, J Lacroix, H Suy, R
Citation: J. Bellemans et al., Arterial occlusion and thrombus aspiration after total knee arthroplasty, CLIN ORTHOP, (366), 1999, pp. 164-168
Antifactor VIII antibody inhibiting allogeneic but not antologous factor VIII in patients with mild hemophilia A
Authors: Peerlinck, K Jacquemin, MG Arnout, J Hoylaerts, MF Gilles, JGG Lavend'homme, R Johnson, KM Freson, K Scandella, D Saint-Remy, JMR Vermylen, J
Citation: K. Peerlinck et al., Antifactor VIII antibody inhibiting allogeneic but not antologous factor VIII in patients with mild hemophilia A, BLOOD, 93(7), 1999, pp. 2267-2273
Inhibitory and activating human antiplatelet antibodies
Authors: Deckmyn, H Vanhoorelbeke, K Peerlinck, K
Citation: H. Deckmyn et al., Inhibitory and activating human antiplatelet antibodies, BAIL CLIN H, 11(2), 1998, pp. 343-359
Optimal care of inhibitor patients during surgery
Authors: Vermylen, J Peerlinck, K
Citation: J. Vermylen et K. Peerlinck, Optimal care of inhibitor patients during surgery, EUR J HAEMA, 61, 1998, pp. 15-17
Drugs affecting blood coagulation, fibrinolysis, and hemostasis
Authors: Peerlinck, K Vermylen, J
Citation: K. Peerlinck et J. Vermylen, Drugs affecting blood coagulation, fibrinolysis, and hemostasis, SIDE EFFECT, 21, 1998, pp. 358-360
Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors - Experience in the Netherlands and Belgium.
Authors: Mauser-Bunschoten, EP de Goede-Bolder, A Wielenga, JJ Levi, M Peerlinck, K
Citation: Ep. Mauser-bunschoten et al., Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors - Experience in the Netherlands and Belgium., NETH J MED, 53(6), 1998, pp. 249-255
Risultati: 1-14 |